|
|
|
Dear [fullname,fallback=Recipient's name],
|
|
Please join us for our ATS Industry Innovations Webinar.
|
|
Dr. Aaron B. Waxman will review the latest developments from the AHA Scientific Sessions 2020 for sotatercept—an investigational agent being studied in clinical trials that may address a key driver of
PAH progression. He will discuss how this potential therapy aims to rebalance BMPR2 signaling and explain the importance of this mechanistic direction.
|
|
A Potential Therapy for Rebalancing BMPR2:
|
|
A New Direction in PAH
|
|
|
|
Featuring Aaron B. Waxman, MD, PhD
|
|
Wednesday, November 18th at 6:30 PM EST including a live Q&A session
|
|
Topic overview
|
|
Despite multiple treatment options, patients with PAH still face a devastating and progressive disease. This program will focus on
the imbalances in BMPR2 and activin receptor signaling that may drive PAH progression, reviewing the latest data available.
A new therapeutic approach that aims to rebalance this signaling will be discussed in the context of potential disease modification.
|
|
|
|
Register for this ATS Industry Innovations Webinar today!
|
|
|
|
|
|
|
Acceleron is passionate about accelerating the discovery of novel therapies that can help patients with PAH and other rare diseases. We hope you find this presentation helpful as we look to the future of PAH therapy.
|
|
|
|